MiReven Receives further $500k from MRCF

MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, today announced that it had received a further AU$500K investment from the Medical Research Commercialisation Fund (MRCF) due to the successful completion of various technical and commercial milestones. This brings the total that […]

Silence Therapeutics signs collaboration with MiReven Pty Ltd to evaluate delivery of novel microRNA-based therapeutics

London, UK, August 22, 2012 – Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with MiReven Pty Ltd (“MiReven”), to assess the delivery potential of Silence’s proprietary delivery systems with MiReven’s novel microRNA-based therapeutics. MiReven, an Australian-based microRNA company, is commercialising discoveries from […]